Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov;27(11):3421-3429.
doi: 10.1681/ASN.2015091065. Epub 2016 Apr 14.

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors

Affiliations

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors

Sagar U Nigwekar et al. J Am Soc Nephrol. 2016 Nov.

Abstract

Accurate identification of risk factors for calcific uremic arteriolopathy (CUA) is necessary to develop preventive strategies for this morbid disease. We investigated whether baseline factors recorded at hemodialysis initiation would identify patients at risk for future CUA in a matched case-control study using data from a large dialysis organization. Hemodialysis patients with newly diagnosed CUA (n=1030) between January 1, 2010, and December 31, 2014, were matched by age, sex, and race in a 1:2 ratio to hemodialysis patients without CUA (n=2060). Mean ages for patients and controls were 54 and 55 years, respectively; 67% of participants were women and 49% were white. Median duration between hemodialysis initiation and subsequent CUA development was 925 days (interquartile range, 273-2185 days). In multivariable conditional logistic regression analyses, diabetes mellitus; higher body mass index; higher levels of serum calcium, phosphorous, and parathyroid hormone; and nutritional vitamin D, cinacalcet, and warfarin treatments were associated with increased odds of subsequent CUA development. Compared with patients with diabetes receiving no insulin injections, those receiving insulin injections had a dose-response increase in the odds of CUA involving lower abdomen and/or upper thigh areas (odds ratio, 1.49; 95% confidence interval, 1.03 to 2.51 for one or two injections per day; odds ratio, 1.88; 95% confidence interval, 1.30 to 3.43 for 3 injections per day; odds ratio, 3.74; 95% confidence interval, 2.28 to 6.25 for more than three injections per day), suggesting a dose-effect relationship between recurrent skin trauma and CUA risk. The presence of risk factors months to years before CUA development observed in this study will direct the design of preventive strategies and inform CUA pathobiology.

Keywords: clinical epidemiology; diabetes mellitus; end stage kidney disease; hemodialysis; obesity; vascular calcification.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Multivariable conditional logistic regression model showing ORs of future CUA development by patient characteristics at hemodialysis initiation. Filled diamond denotes point estimate of ORs and error bars represent 95% CI. ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; ESA, erythropoiesis-stimulating agents; sPKtV, single pool KtV.
Figure 2.
Figure 2.
ORs of future CUA involving lower abdomen and/or upper thigh areas by number of insulin injections per day at hemodialysis initiation. Model 1 is an unadjusted model; model 2 is adjusted for age, race, and sex; model 3 is adjusted for covariates independently associated with increased risk of CUA involving lower abdomen and/or upper thigh areas in patients with diabetes mellitus. *P<0.05 (significant difference from reference values; zero insulin injections per day).

Comment in

  • Calcific Uremic Arteriolopathy Revisited.
    Jovanovich A, Chonchol M. Jovanovich A, et al. J Am Soc Nephrol. 2016 Nov;27(11):3233-3235. doi: 10.1681/ASN.2016040480. Epub 2016 May 25. J Am Soc Nephrol. 2016. PMID: 27225039 Free PMC article. No abstract available.

Similar articles

Cited by

References

    1. Hayden MR, Kolb LG, Khanna R: Calciphylaxis and the cardiometabolic syndrome. J Cardiometab Syndr 1: 76–79, 2006 - PubMed
    1. Nigwekar SU, Solid CA, Ankers E, Malhotra R, Eggert W, Turchin A, Thadhani RI, Herzog CA: Quantifying a rare disease in administrative data: the example of calciphylaxis. J Gen Intern Med 29[Suppl 3]: S724–S731, 2014 - PMC - PubMed
    1. Nigwekar SU, Bhan I, Turchin A, Skentzos SC, Hajhosseiny R, Steele D, Nazarian RM, Wenger J, Parikh S, Karumanchi A, Thadhani R: Statin use and calcific uremic arteriolopathy: a matched case-control study. Am J Nephrol 37: 325–332, 2013 - PMC - PubMed
    1. Angelis M, Wong LL, Myers SA, Wong LM: Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122: 1083–1089, discussion 1089–1090, 1997 - PubMed
    1. Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y Japanese Calciphylaxis Study Group : A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27: 1580–1584, 2012 - PubMed